ESTA vs PEN
ESTA: A global medical technology company revolutionizing the breast aesthetics and reconstruction market through its proprietary, safety-focused Motiva Implants and minimally invasive surgical platforms. PEN: Penumbra is a medical device innovator specializing in mechanical thrombectomy and embolization technologies to treat neurovascular and peripheral vascular conditions.
Side-by-side fundamentals
| Metric | ESTA | PEN | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $92.54 | $321.19 | |
| Market cap as of 2026-08-03 | $2.7B | $12.7B | |
| P/E as of 2026-08-03 | n/a | 73.92 | |
| PEG as of 2026-08-03 | n/a | 9.85 | |
| Net margin as of 2026-08-03 | -19.1% | +11.8% | PEN higher |
| Gross margin as of 2026-08-03 | +70.1% | +67.4% | ESTA higher |
| Operating margin as of 2026-08-03 | -12.4% | +12.9% | PEN higher |
| ROE as of 2026-08-03 | -225.9% | +12.3% | PEN higher |
| ROA as of 2026-08-03 | -12.7% | +9.6% | PEN higher |
| Debt / equity as of 2026-08-03 | 17.58 | 0.02 | PEN lower |
| Revenue growth (YoY) as of 2026-08-03 | +34.9% | +17.3% | ESTA higher |
| Revenue CAGR (3y) SEC XBRL | +9.3% | +18.3% | PEN higher |
| Beta as of 2026-08-03 | 1.84 | 0.53 | |
| 1-year return as of 2026-07-31 close | +120.5% | +27.3% | ESTA higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.